Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sugammadex in Renal Diseased Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 65 years old~* end-stage renal disease defined by clearance of creatinine \< 30 ml/min~* normal renal function defined by clearance if creatinine \> 90 ml/min~* candidates to elective surgical procedures (control group) or kidney transplantation (renal group) under general anaesthesia~Exclusion Criteria:~* pregnant and breastfeeding women~* patients with known or suspected neuromuscular disorders~* patients with hepatic disfunction~* a history of malignant hyperthermia~* allergy to narcotics, rocuronium or other medication used during general anaesthesia~* patients receiving medication known to interfere with the action of rocuronium (amino glycoside antibiotics, anticonvulsants, or magnesium)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Renal Group (Type: EXPERIMENTAL): Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
- Control group (Type: ACTIVE_COMPARATOR): Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade

Based on this trial design, predict the completion outcome and termination type (if applicable).